Decades of research, one of the most well-studied peptides in the catalog. A plain-language summary of what the evidence actually shows.
GHK-Cu — the tripeptide glycyl-L-histidyl-L-lysine bound to a copper(II) ion — is among the most extensively studied peptides in the longevity and skin literature. It was first isolated by Loren Pickart in 1973 from human plasma, where it appears in concentrations of roughly 200 ng/mL in young adults and declines with age. Five decades of research have followed.
This is a plain-language summary of what that research actually shows — where the evidence is strong, where it is suggestive, and where the marketing has run ahead of the data.
GHK is a sequence of three amino acids that binds copper with very high affinity. In the body, GHK-Cu functions as a copper-shuttling peptide — delivering copper ions to tissues where copper-dependent enzymes can use them. Copper is a cofactor for several enzymes critical to skin remodeling, collagen synthesis, and antioxidant defense.
The peptide is small (~340 Daltons), water-soluble, and stable in solution under refrigeration. It is the bound form — GHK-Cu — that is biologically active, not the bare tripeptide. The copper is structural to the molecule's function.
The strongest body of evidence for GHK-Cu is in wound healing, particularly in animal models. Studies in rats, mice, and pigs through the 1980s and 1990s consistently showed that topical GHK-Cu accelerated wound closure, increased collagen synthesis at the wound site, and improved the organization of healing tissue. Several mechanisms have been proposed: stimulation of fibroblast proliferation, recruitment of immune cells to the wound site, modulation of matrix metalloproteinases (the enzymes that remodel tissue), and increased copper-dependent antioxidant activity.
Human studies are smaller and more heterogeneous, but the direction of effect is consistent with the animal work. A 2009 study by Pickart and colleagues reviewed clinical results in chronic wound healing and reported improved closure rates in diabetic ulcers.
By the 2000s, the interest had broadened from wound healing into cosmetic and anti-aging applications. GHK-Cu is included in a number of dermatological formulations marketed for skin firmness, fine lines, and elasticity.
The mechanistic case for skin effects is reasonable. GHK-Cu has been shown in vitro to stimulate production of collagen types I and III, elastin, glycosaminoglycans, and proteoglycans — the structural and water-binding components of healthy dermis. It also appears to reduce the expression of matrix metalloproteinases that break down those same components. In other words: it pushes the balance toward synthesis and away from degradation, at least in cell culture.
Clinical evidence in humans is more limited than the in vitro work, but several small studies have reported improvements in skin firmness, density, and clarity over 12–24 weeks of topical application. The effect sizes are modest. The studies are short. None of this is dramatic transformation; it is a slow nudge in a favorable direction.
The most provocative GHK-Cu research is in gene expression. A 2010 paper by Pickart and Margolina, expanded in subsequent work, examined the effect of GHK on cultured human cells using the Connectivity Map — a database of how various compounds shift the expression patterns of thousands of genes simultaneously.
GHK was found to modulate expression of roughly 30% of the 21,000 human genes examined, with a pattern resembling a partial reversal of the gene-expression signature of aging. The peptide increased expression of DNA repair genes, antioxidant genes, and immune-regulatory genes, and decreased expression of pro-inflammatory and apoptotic genes.
This finding is intriguing but easy to overstate. It is in vitro work in cultured cells. The phrase “reversal of aging” that has spread through wellness media is not a fair characterization of what the data shows. What the data shows is that GHK-Cu has broad, generally favorable effects on cellular gene expression in a dish. Whether those effects translate to a meaningful organismal outcome in humans is an open question.
Three things are not well-established in the GHK-Cu literature:
Optimal dosing and route. Most clinical work is topical. Subcutaneous injection is increasingly used by researchers but is supported primarily by tradition rather than dose-finding studies in humans. Effective concentrations vary widely across the literature.
Long-term safety in chronic injection. Topical GHK-Cu has a strong safety record. Subcutaneous administration in humans over years has not been formally studied. Animal studies suggest a wide safety margin, but extrapolation has limits.
Bioavailability and degradation in plasma. GHK is cleaved by plasma peptidases relatively quickly. How much of an injected dose actually reaches the target tissues, and in what form, is not fully characterized.
The honest summary is this: GHK-Cu has a well-established role in wound healing, a plausible and partially-supported role in skin remodeling, and a fascinating but preliminary set of findings in cellular gene expression. The peptide is one of the most thoroughly studied small molecules in its class. It is not magic, and it is not snake oil. It is a tool with a documented mechanism and a documented record of effect, with limits the marketing rarely acknowledges.
For researchers interested in the underlying papers, Pickart's published work spans 1973 to the present and provides the spine of the literature. The 2018 Pickart and Margolina review in Cosmetics (vol. 5, no. 1) is a useful entry point.
Our GHK-Cu offerings are available in 50mg and 100mg vials, with COAs supplied on request.
This article is provided for informational and educational purposes only. Lumira Labs products are sold strictly for laboratory research use and are not for human consumption, medical use, or veterinary application. The compounds discussed are not approved by Health Canada or the FDA for any therapeutic indication. Nothing in this article should be construed as medical advice.